Silence Therapeutics aims at Takeda with new data in rare blood cancer

Silence cashes in on ‘differentiated’ data; UK reaffirms support for childhood vaccines

Some analysts believe Silence’s polycythemia vera drug could be superior to a closely watched Takeda medicine. Elsewhere, the FDA spurned a radiopharmaceutical and AbCellera shares climbed to levels not seen since 2023.